BPC-157/TB-500 Blend vs ARA-290
Side-by-side comparison of BPC-157/TB-500 Blend and ARA-290: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
BPC-157/TB-500 Blend
ARA-290
BPC-157/TB-500 Blend
Combined healing peptide blend
Lowest listed price: $49.99 across 6 listings
Full BPC-157/TB-500 Blend profileARA-290
ARA-290, also known as Cibinetide or pHBSP (Helix B Surface Peptide), is an 11-amino-acid peptide — QEQLERALNSS — designed to mimic a specific region of the tissue-protective surface of erythropoietin (EPO) without…
Lowest listed price: $32.00 across 5 listings
Full ARA-290 profileSide-by-side comparison
| Attribute | BPC-157/TB-500 Blend | ARA-290 |
|---|---|---|
| Category | Recovery | Recovery |
| Research Stage | Preclinical | Phase 2 |
| Mechanism of Action | A combination of BPC-157 and TB-500 (thymosin beta-4) in a single formulation. It pairs BPC-157's angiogenic, pro-healing activity - driven largely through VEGFR2 and nitric-oxide (Akt-eNOS) signaling (PMID: 40789979) - with TB-500's actin… | ARA-290's mechanism of action is one of the more elegantly engineered examples of pharmaceutical design in the peptide space. Understanding it requires appreciation of the dual-receptor biology of erythropoietin and the specific receptor-selective engineering… |
| Half-Life | BPC-157: short - under ~30 min in animal PK studies (rats/dogs); no human PK data. TB-500 (thymosin beta-4): active fragment ~30 min, though tissue effects are prolonged. | ~2 minutes (plasma half-life; downstream tissue-protective effects persist hours to days) |
| Typical Dose Range | Dosed per component (a fixed daily blend over-doses TB-500 - see notes). BPC-157: 250-500 mcg once daily SUBQ. TB-500 (thymosin beta-4): 2-2.5 mg twice weekly during a 4-6 week loading phase, then 2-2.5 mg once weekly for maintenance (~5 mg/week during loading). If a pre-blended fixed-ratio daily vial is used, its TB-500 fraction should be ~250-350 mcg per injection so the weekly TB-500 total stays near ~5 mg. | 1 mg - 4 mg subcutaneous daily |
| Dosing Frequency | BPC-157: once daily SUBQ. TB-500: twice weekly during the loading phase, then maintenance ~2-3x/week or once weekly for TB-500 as needed. | Once daily |
| Administration | Subcutaneous, Intramuscular | — |
| Side Effects | See individual compounds. Generally well-tolerated. Injection site reactions, mild nausea, headache. Rare: temporary fatigue. | ARA-290 has demonstrated a notably favorable safety profile across clinical trials — one of the cleaner safety records among research peptides. The engineering rationale of separating tissue-protective effects from hematopoietic effects appears to have largely… |
| Molecular Weight | BPC-157: ~1419.5 g/mol (average; molecular formula C62H98N16O22). TB-500 (thymosin beta-4): ~4963 Da (full 43-residue peptide). | ~1257 Da |
| Common Vial Sizes | 5mg, 10mg | — |
Price History
4 data points- OF
- BM
- Half Nattys
- BHG Labs
- RC
Price History
3 data points- Ion Peptide
- BHG Labs
- LB
BPC-157/TB-500 Blend: potential benefits
- Accelerated tissue healing (preclinical/anecdotal)
- Reduced recovery time
- Anti-inflammatory support
- Complementary repair mechanisms: angiogenesis (BPC-157) plus actin-regulated cell migration (TB-500)
ARA-290: potential benefits
- Neuroprotective effects
- Anti-inflammatory activity
- Tissue repair without erythropoiesis
- Potential diabetic neuropathy treatment
- Sarcoidosis symptom reduction
Frequently asked
What's the difference between BPC-157/TB-500 Blend and ARA-290?
BPC-157/TB-500 Blend is a recovery that a combination of bpc-157 and tb-500 (thymosin beta-4) in a single formulation. it pairs bpc-157's angiogenic, pro-healing activity - driven largely through vegfr2 and nitric-oxide…. ARA-290 is a recovery that ara-290's mechanism of action is one of the more elegantly engineered examples of pharmaceutical design in the peptide space. understanding it requires appreciation of the…. The two differ in mechanism, half-life (BPC-157: short - under ~30 min in animal PK studies (rats/dogs); no human PK data. TB-500 (thymosin beta-4): active fragment ~30 min, though tissue effects are prolonged. vs ~2 minutes (plasma half-life; downstream tissue-protective effects persist hours to days)), and typical dose range.
Which has the longer half-life, BPC-157/TB-500 Blend or ARA-290?
BPC-157/TB-500 Blend has a half-life of BPC-157: short - under ~30 min in animal PK studies (rats/dogs); no human PK data. TB-500 (thymosin beta-4): active fragment ~30 min, though tissue effects are prolonged.. ARA-290 has a half-life of ~2 minutes (plasma half-life; downstream tissue-protective effects persist hours to days). Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, BPC-157/TB-500 Blend or ARA-290?
Lowest listed price on BodyHackGuide: BPC-157/TB-500 Blend from $49.99, ARA-290 from $32.00. Prices are pulled from the vendor listings tracked on BHG and change frequently. See the compare tables on each compound page for the current set of offers.
Can you stack BPC-157/TB-500 Blend and ARA-290?
Stacking depends on mechanism overlap, safety profile, and goals. BPC-157/TB-500 Blend and ARA-290 should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy BPC-157/TB-500 Blend or ARA-290
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. We earn an affiliate commission on some outbound clicks, and every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.